

Figure 1: Electroretinogram (ERG): Development of b-wave amplitude of study eyes (n=24) following administration of verum and placebo.




Figure 2: Farnsworth-Munsell D100 one hour after administration for all study eyes (n=24)

INTRAOCULAR PRESSURE (MMHG) FOR STUDY EYE  
(ALL SUBJECTS VALID FOR PK/PD AND SAFETY, N=24)

TREATMENT	TIME	N	MEAN	SD	MINIMUM	MEDIAN	MAXIMUM
NONE	SCREENING	24	16.1	2.2	12	16.0	19
PLACEBO	OD 00H 20MIN	24	14.8	1.8	12	15.0	18
	OD 05H 20MIN	24	15.3	2.1	10	16.0	18
	1D 00H 00MIN	24	15.1	2.1	11	16.0	19
VERUM	OD 00H 20MIN	24	15.7	2.0	12	16.0	19
	OD 05H 20MIN	24	16.1	2.1	12	16.0	19
	1D 00H 00MIN	24	15.0	2.4	11	15.0	19

Table 1: Intraocular pressure (mmHg), (mean ± SD)

TREATMENT	TIME	N	MEAN	GM(MD)			
				SD	MINIMUM	MEDIAN	MAXIMUM
NONE	SCREENING	24	1.29	1.76	-2.8	1.50	4.0
PLACEBO	OD 05H 20MIN	24	0.67	2.38	-7.2	1.10	3.6
	1D 00H 00MIN	24	1.59	1.45	-0.7	1.10	5.0
VERUM	OD 05H 20MIN	24	1.30	1.61	-1.6	1.25	4.1
	1D 00H 00MIN	24	1.26	1.45	-1.3	1.05	4.3

Table 2: Humphrey 30-2 visual field (dB), mean deviation (MD), (mean ± SD)

VISUAL ACUITY - LOG MAR FOR STUDY EYE  
(ALL SUBJECTS VALID FOR PK/PD AND SAFETY, N=24)

TREATMENT	TIME	N	MEAN	SD	MINIMUM	MEDIAN	MAXIMUM
NONE	SCREENING	24	-0.068	0.081	-0.24	-0.070	0.12
PLACEBO	OD 00H 20MIN	24	-0.079	0.075	-0.28	-0.070	0.02
	OD 05H 20MIN	24	-0.078	0.075	-0.26	-0.060	0.02
	1D 00H 00MIN	24	-0.097	0.079	-0.28	-0.080	0.00
VERUM	OD 00H 20MIN	24	-0.087	0.069	-0.24	-0.080	0.02
	OD 05H 20MIN	24	-0.061	0.059	-0.18	-0.060	0.02
	1D 00H 00MIN	24	-0.082	0.083	-0.24	-0.100	0.12

Table 3: Best corrected visual acuity (LogMAR), (mean ± SD)

	40 mg BAY 38-9456 N = 24	BAY 38-9456 placebo N = 24	Difference active - placebo
<b>a-wave</b>			
Screening	22.3 ± 1.0	22.3 ± 1.0	
1 h 20 min post administration	23.0 ± 1.6	22.6 ± 0.9	0.4 ± 1.4
6 h 20 min post administration	22.4 ± 1.0	22.6 ± 0.9	-0.2 ± 0.8
24 h post administration	22.6 ± 0.8	22.8 ± 1.1	-0.2 ± 0.8
<b>b-wave</b>			
Screening	43.1 ± 3.1	43.1 ± 3.1	
1 h 20 min post administration	43.1 ± 4.1	43.8 ± 2.5	-0.7 ± 3.8
6 h 20 min post administration	44.0 ± 2.4	43.8 ± 2.2	0.2 ± 2.7
24 h post administration	43.8 ± 1.8	43.9 ± 2.7	-0.2 ± 2.2

Table 4: ERG latency (msec), 2.4 cds/m<sup>2</sup> (mean ± SD)

	40 mg BAY 38-9456 N = 24	BAY 38-9456 placebo N = 24	Difference active - placebo
<b>a-wave</b>			
Screening	14.4 ± 1.3	14.4 ± 1.3	
1 h 20 min post administration	15.0 ± 2.1	14.5 ± 2.0	0.5 ± 2.2
6 h 20 min post administration	15.1 ± 2.2	14.4 ± 1.5	0.7 ± 2.2
24 h post administration	14.3 ± 2.1	14.3 ± 2.2	-0.0 ± 2.9
<b>b-wave</b>			
Screening	29.1 ± 1.7	29.1 ± 1.7	
1 h 20 min post administration	29.5 ± 1.7	29.0 ± 1.4	0.5 ± 1.4
6 h 20 min post administration	28.8 ± 1.6	28.7 ± 1.1	0.0 ± 1.5
24 h post administration	28.9 ± 1.5	28.9 ± 1.8	-0.1 ± 1.2

Table 5: ERG latency (msec), 5 cds/m<sup>2</sup> (mean ± SD)